Search Result

Results for "

lysine acetyltransferase

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Histone Acetyltransferase (1) Aldehyde Dehydrogenase (ALDH) (1) Apoptosis (1) Bacterial (1) Chemerin Receptor (1) Cholinesterase (ChE) (1) Epigenetic Reader Domain (1) MDM-2/p53 (1)
By Research Areas:	Cancer (5) Infection (1) Inflammation/Immunology (1)

Inhibitors & Agonists

Screening Libraries

Recombinant Proteins

Targets Recommended: Histone Acetyltransferase

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-W015239

KAT8-IN-1 1 Publications Verification	Others	Inflammation/Immunology Cancer
KAT8-IN-1 is a lysine (K) acetyltransferase 8 (KAT8) inhibitor, with IC₅₀s of 141 μM (KAT8), 221 μM (KAT2B), 106 μM (KAT3B), respectively. KAT8 inhibits histone acetyltransferases (HATs), and could result in disease states, such as cancer or inflammatory diseases .

HY-145286

IMPDH2-IN-2	Bacterial	Infection Cancer
IMPDH2-IN-2 is a potent inhibitor of inosine 5’-monophosphate dehydrogenase (IMPDH) with a K_i,app value of 14 μM, respectively. IMPDH2-IN-2 displays moderate antibacterial activity (MIC = 6.3 and 11 μM in minimal GAST/Fe and rich 7H9/ADC/Tween media, respectively). IMPDH2-IN-2 is a potential anti-tuberculosis agent .

HY-138097

α-NETA 5+ Cited Publications	Chemerin Receptor Aldehyde Dehydrogenase (ALDH) Cholinesterase (ChE) Apoptosis	Cancer
α-NETA is a potent and noncompetitive choline acetyltransferase (ChA) inhibitor with an IC₅₀ of 9 μM. α-NETA is a potent ALDH1A1 (IC₅₀=0.04 µM) and chemokine-like receptor-1 (CMKLR1) antagonist. α-NETA weakly inhibits cholinesterase (ChE; IC₅₀=84 µM) and acetylcholinesterase (AChE; IC₅₀=300 µM). α-NETA has anti-cancer activity .

HY-139861

CBP/p300-IN-14	Epigenetic Reader Domain Histone Acetyltransferase	Cancer
CBP/p300-IN-14 is a potent inhibitor of CBP/EP300 (lysine acetyltransferase) with an IC₅₀ of 3.3 nM (extracted from patent WO2021213521A1, compound 27) .

HY-159606

MS182	MDM-2/p53	Cancer
MS182 (compound 11) is an acetylation targeting chimera (AceTAC) designed based on p53 ^Y220C stabilizer and targeting p53 ^Y220C. MS182 is composed of p53 ^Y220C and p300/CBP binders, respectively, coupled by a linker. MS182 forms a ternary complex with p300/CBP acetyltransferase and p53 ^Y220C in a time- and concentration-dependent manner, effectively acetylating lysine at position 382 of p53 ^Y220C (ACE₅₀: 1.52 μM). MS182 also exhibited considerable bioavailability in mice, with GI₅₀ values of 2.16 μM and 1.83 μM for BxPC3 (p53 ^Y220C/-) and NUGC (p53 ^Y220C/+), respectively .

Cat. No.	Product Name

HY-L024

Histone Modification Research Compound Library	621 compounds
A histone modification, a covalent post-translational modification (PTM) to histone proteins, includes methylation, phosphorylation, acetylation, ubiquitylation, and sumoylation, etc. In general, histone modifications are catalyzed by specific enzymes that act predominantly at the histone N-terminal tails involving amino acids such as lysine or arginine, as well as serine, threonine, tyrosine, etc. The PTMs made to histones can impact gene expression by altering chromatin structure or recruiting histone modifiers. Histone modifications act in diverse biological processes such as transcriptional activation/inactivation, chromosome packaging, and DNA damage/repair. Deregulation of histone modification contributes to many diseases, including cancer and autoimmune diseases. MCE owns a unique collection of 621 bioactive compounds targeting Epigenetic Reader Domain, HDAC, Histone Acetyltransferase, Histone Demethylase, Histone Methyltransferase, Sirtuin, etc. Histone Modification Research Compound Library is a useful tool for histone modification research and drug screening.

Histone Modification Research Compound Library

621 compounds

A histone modification, a covalent post-translational modification (PTM) to histone proteins, includes methylation, phosphorylation, acetylation, ubiquitylation, and sumoylation, etc. In general, histone modifications are catalyzed by specific enzymes that act predominantly at the histone N-terminal tails involving amino acids such as lysine or arginine, as well as serine, threonine, tyrosine, etc. The PTMs made to histones can impact gene expression by altering chromatin structure or recruiting histone modifiers. Histone modifications act in diverse biological processes such as transcriptional activation/inactivation, chromosome packaging, and DNA damage/repair. Deregulation of histone modification contributes to many diseases, including cancer and autoimmune diseases.

MCE owns a unique collection of 621 bioactive compounds targeting Epigenetic Reader Domain, HDAC, Histone Acetyltransferase, Histone Demethylase, Histone Methyltransferase, Sirtuin, etc. Histone Modification Research Compound Library is a useful tool for histone modification research and drug screening.

Species:	Human (2) E.coli (2)
Tag:	His (2) Tag Free (2) Strep (1)
Source:	E. coli (4)

Cat. No.	Compare	Product Name	Species	Source

HY-P71707

	KAT5 Protein, Human (His) 60kDa Tat interactive protein; cPLA2 interacting protein; ESA1; Histone acetyltransferase HTATIP; HTATIP1; K(lysine) acetyltransferase 5; PLIP; Tat interacting protein, 60kDa; TIP; Tip60	Human	E. coli
	The KAT5 protein is the catalytic subunit of the NuA4 histone acetyltransferase complex and activates gene transcription through histone acetylation. KAT5 Protein, Human (His) is the recombinant human-derived KAT5 protein, expressed by E. coli , with N-6*His labeled tag. The total length of KAT5 Protein, Human (His) is 511 a.a., with molecular weight of ~62.4 kDa.

HY-P701956

	patZ Protein, E.coli patZ; Peptidyl-lysine N-acetyltransferase PatZ; Protein lysine acetyltransferase	E.coli	E. coli
	The patZ protein catalyzes the acetylation of lysine residues in a variety of target proteins, including RNase R and RNase II, during exponential phase. patZ Protein, E.coli is the recombinant E. coli-derived patZ protein, expressed by E. coli , with tag free. The total length of patZ Protein, E.coli is 885 a.a., .

HY-P701957

	patZ Protein, E.coli (His, Strep) patZ; Peptidyl-lysine N-acetyltransferase PatZ; Protein lysine acetyltransferase	E.coli	E. coli
	The patZ protein catalyzes the acetylation of lysine residues in a variety of target proteins, including RNase R and RNase II, during exponential phase. patZ Protein, E.coli (His, Strep) is the recombinant E. coli-derived patZ protein, expressed by E. coli , with N-Strep, N-6*His labeled tag. The total length of patZ Protein, E.coli (His, Strep) is 885 a.a., .

HY-P701625

	MYST1 Protein, Human KAT8; Histone acetyltransferase KAT8; lysine acetyltransferase 8; MOZ; YBF2/SAS3; SAS2 and TIP60 protein 1; MYST-1; hMOF	Human	E. coli
	The MYST1 protein is a histone acetyltransferase associated with transcriptional activation and potential regulation of gene expression. In addition to transcription, MYST1 may also affect ATM function. MYST1 Protein, Human is the recombinant human-derived MYST1 protein, expressed by E. coli , with tag free. The total length of MYST1 Protein, Human is 458 a.a., .

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.